432,748 Shares in DaVita Inc. $DVA Acquired by Norges Bank

Norges Bank purchased a new position in shares of DaVita Inc. (NYSE:DVA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 432,748 shares of the company’s stock, valued at approximately $49,164,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Elevation Wealth Partners LLC boosted its stake in DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after buying an additional 165 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of DaVita in the 2nd quarter worth approximately $43,000. iSAM Funds UK Ltd acquired a new position in shares of DaVita in the 3rd quarter worth approximately $46,000. Stance Capital LLC purchased a new position in shares of DaVita during the 3rd quarter worth approximately $47,000. Finally, Fideuram Asset Management Ireland dac acquired a new stake in DaVita in the 4th quarter valued at approximately $49,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

DVA opened at $192.28 on Monday. DaVita Inc. has a one year low of $101.00 and a one year high of $202.69. The company has a market cap of $12.34 billion, a P/E ratio of 17.84, a PEG ratio of 0.63 and a beta of 0.91. The business’s 50-day simple moving average is $171.47 and its 200-day simple moving average is $143.36.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same period last year, the business earned $2.00 EPS. DaVita’s revenue for the quarter was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts predict that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on DVA. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and lifted their target price for the company from $126.00 to $220.00 in a research report on Wednesday, May 6th. Barclays boosted their price target on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Finally, Truist Financial raised their price objective on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $199.17.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.